DDO-2213

DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research[1].

Product Specifications

CAS Number

[2378768-36-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

WDR5

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ddo-2213.html

Purity

98.84

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(C2=CC(NC3=NC=NC(Cl)=C3N)=C(N4CCN(C)CC4)C=C2F)C=C1)N(C)C

Molecular Formula

C24H27ClFN7O

Molecular Weight

483.97

Precautions

H302, H315, H319, H335

References & Citations

[1]Chen W, et al. Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. J Med Chem. 2021 Jun 24;64 (12) :8221-8245.